[{"address1": "4 Kingsbury Avenue", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 607 0800", "fax": "617 607 0530", "website": "https://www.enanta.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 131, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay R. Luly Ph.D.", "age": 68, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1231428, "exercisedValue": 0, "unexercisedValue": 67815}, {"maxAge": 1, "name": "Mr. Paul J. Mellett Jr.", "age": 69, "title": "Chief Financial & Administrative Officer", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 671700, "exercisedValue": 0, "unexercisedValue": 21320}, {"maxAge": 1, "name": "Dr. Yat Sun Or Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 740108, "exercisedValue": 0, "unexercisedValue": 22091}, {"maxAge": 1, "name": "Mr. Matthew P. Kowalsky J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 575652, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott T. Rottinghaus M.D.", "age": 50, "title": "Chief Medical Office", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 776138, "exercisedValue": 43483, "unexercisedValue": 14728}, {"maxAge": 1, "name": "Ms. Jennifer  Viera", "title": "Executive Director of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathaniel S. Gardiner J.D.", "age": 70, "title": "Consultant", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 672675, "exercisedValue": 49136, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tara Lynn Kieffer Ph.D.", "age": 46, "title": "Chief Product Strategy Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 496852, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan  Luu", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 622856, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 4, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.98, "open": 6.92, "dayLow": 6.5, "dayHigh": 7.04, "regularMarketPreviousClose": 6.98, "regularMarketOpen": 6.92, "regularMarketDayLow": 6.5, "regularMarketDayHigh": 7.04, "payoutRatio": 0.0, "beta": 0.772, "forwardPE": -1.3609958, "volume": 174603, "regularMarketVolume": 174603, "averageVolume": 164621, "averageVolume10days": 162280, "averageDailyVolume10Day": 162280, "bid": 6.52, "ask": 6.62, "bidSize": 1, "askSize": 1, "marketCap": 140230496, "fiftyTwoWeekLow": 4.09, "fiftyTwoWeekHigh": 17.235, "priceToSalesTrailing12Months": 2.175364, "fiftyDayAverage": 6.6102, "twoHundredDayAverage": 7.401325, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 184373952, "profitMargins": -1.49566, "floatShares": 14358649, "sharesOutstanding": 21376600, "sharesShort": 2498915, "sharesShortPriorMonth": 2854687, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.1169, "heldPercentInsiders": 0.06565, "heldPercentInstitutions": 0.87517, "shortRatio": 14.96, "shortPercentOfFloat": 0.1242, "impliedSharesOutstanding": 22745200, "bookValue": 4.376, "priceToBook": 1.4990859, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -96415000, "trailingEps": -4.53, "forwardEps": -4.82, "enterpriseToRevenue": 2.86, "enterpriseToEbitda": -1.863, "52WeekChange": -0.6033857, "SandP52WeekChange": 0.1116153, "quoteType": "EQUITY", "currentPrice": 6.56, "targetHighPrice": 24.0, "targetLowPrice": 5.0, "targetMeanPrice": 15.2, "targetMedianPrice": 20.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 193375008, "totalCashPerShare": 9.046, "ebitda": -98944000, "totalDebt": 216142000, "quickRatio": 5.093, "currentRatio": 5.286, "totalRevenue": 64463000, "debtToEquity": 231.074, "revenuePerShare": 3.035, "returnOnAssets": -0.17329, "returnOnEquity": -0.74265, "grossProfits": 64463000, "freeCashflow": -72374624, "operatingCashflow": -55464000, "revenueGrowth": -0.125, "grossMargins": 1.0, "ebitdaMargins": -1.5349001, "operatingMargins": -1.6432401, "financialCurrency": "USD", "symbol": "ENTA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -6.01719, "regularMarketPrice": 6.56, "shortName": "Enanta Pharmaceuticals, Inc.", "longName": "Enanta Pharmaceuticals, Inc.", "marketState": "CLOSED", "cryptoTradeable": false, "firstTradeDateMilliseconds": 1363872600000, "postMarketChangePercent": -0.30487776, "postMarketPrice": 6.54, "postMarketChange": -0.01999998, "regularMarketChange": -0.42, "regularMarketDayRange": "6.5 - 7.04", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 164621, "fiftyTwoWeekLowChange": 2.4699998, "fiftyTwoWeekLowChangePercent": 0.60391194, "fiftyTwoWeekRange": "4.09 - 17.235", "fiftyTwoWeekHighChange": -10.675001, "fiftyTwoWeekHighChangePercent": -0.6193792, "fiftyTwoWeekChangePercent": -60.33857, "earningsTimestamp": 1747080060, "earningsTimestampStart": 1754305140, "earningsTimestampEnd": 1754654400, "earningsCallTimestampStart": 1715027400, "earningsCallTimestampEnd": 1715027400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -4.53, "epsForward": -4.82, "epsCurrentYear": -3.894, "priceEpsCurrentYear": -1.684643, "fiftyDayAverageChange": -0.050199986, "fiftyDayAverageChangePercent": -0.007594322, "twoHundredDayAverageChange": -0.8413253, "twoHundredDayAverageChangePercent": -0.11367225, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "hasPrePostMarketData": true, "corporateActions": [], "postMarketTime": 1752271509, "regularMarketTime": 1752264001, "exchange": "NMS", "messageBoardId": "finmb_345286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Enanta Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-07-12"}]